Sharp Therapeutics Corp. News Releases

Sharp Therapeutics Announces Closing of Non-Brokered Private Placement

Wed, 29 Jul 2026 08:45:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement (the "Offering") of common shares in the capital of the Company (the "Common Shares") for aggregate gross proceeds of C$1,365,000 through the issuance of 1,500,000 Common Shares at a price of C$0.91 per Common Share. The net proceeds of the...

Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders

Tue, 21 Jul 2026 17:00:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small molecule therapies to treat genetic diseases, is pleased to announce the voting results from its annual general meeting of shareholders held on July 21, 2026 (the "Meeting").All nominees set forth in the Company's amended and restated management information circular dated June 17, 2026 (the...

Sharp Therapeutics Announces Non-Brokered Private Placement and Provides Operational Update

Wed, 15 Jul 2026 08:00:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it is arranging a non-brokered private placement to raise gross proceeds of up to C$1,365,000 (the "Offering"). The Offering will consist of common shares in the capital of the Company (the "Common Shares") priced at not less than C$0.91 per Common Share. The Company expects the Offering to close in Q3 2026....

Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date

Tue, 30 Jun 2026 17:00:00 -0400

Shareholders Must Recast Their Votes to be Counted Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that its annual meeting of shareholders will be held at 10:00 a.m. (Toronto time) on July 21, 2026 (the "Meeting"), having been postponed from the initial meeting date of June 30, 2026.The Company has filed an amended and restated notice of meeting (the "Amended and Restated...

Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting

Fri, 17 Apr 2026 18:13:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its annual audited consolidated financial statements for the year ended December 31, 2025, and related management discussion and analysis ("MD&A") and annual information form. All dollar figures are in United States dollars, unless otherwise stated. Scott Sneddon, Sharp's Chief Executive Officer, stated: "Our...

Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs

Fri, 10 Apr 2026 17:05:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that following longer-term non-GLP testing the company has decided to advance an alternative compound for its Gaucher and GBA1 Parkinson's programs. The company continues to advance all platform programs including programs for genetic and sporadic forms of neurodegeneration (Progranulin modulators), and a rare...

Sharp Therapeutics Announces Closing of Fourth Tranche of Unsecured Convertible Note Offering

Fri, 10 Apr 2026 17:00:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the Fourth Tranche, the...

Sharp Therapeutics Announces Closing of Third Tranche of Unsecured Convertible Note Offering

Thu, 02 Apr 2026 17:43:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the third tranche (the "Third Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the Third Tranche, the Company...

Sharp Therapeutics Announces Closing of Second Tranche of Unsecured Convertible Note Offering

Fri, 13 Mar 2026 17:05:00 -0400

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the Second Tranche, the...

Sharp Therapeutics Announces Closing of First Tranche of Unsecured Convertible Note Offering

Fri, 27 Feb 2026 17:21:00 -0500

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 27, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the First Tranche, the...